Congress scolds Mylan CEO for trying to get 'filthy rich' off EpiPens

Heather Bresch tells House committee the company should have ‘better anticipated’ severity of price hikes and says generic version will be sold soon

US politicians have accused the boss of drug company Mylan of attempting to get “filthy rich” by “jacking up” the price of life-saving allergy treatment EpiPen.

Speaking at a congressional hearing on Wednesday, Elijah Cummings, the ranking Democrat on the House committee on oversight and government reform, accused Mylan chief executive Heather Bresch of exploiting a strategy “to find old cheap drug that has virtually no competition and raise the price over and over and over again as high as you can”.

Related: Mylan CEO sold $5m worth of stock while EpiPen price drew scrutiny

Continue reading…

Pharmaceutical Stocks

[stock-ticker]

© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us